Story perspectives

FDA Declares UniQure's Gene Therapy a "Failed Product"

3/6/2026

Summary

Story summary

A senior official from the U.S. Food and Drug Administration (FDA) called UniQure's Huntington's disease gene therapy a "failed product" during a media call.
The FDA has requested a new placebo-controlled study, disputing UniQure's ethics claim.
The official said UniQure's previous trial design did not demonstrate the therapy's effectiveness.
UniQure's stock rose 19% to $10.75 after the announcement, reflecting the FDA's long-standing policy requiring rigorous trial designs for Huntington's treatments.

History

Historical Context

In 2013, the FDA implemented strict regulations for gene therapies, mandating comprehensive clinical trials to ensure safety and efficacy. This shift followed historical scrutiny of drug approvals, particularly after the Vioxx recall in 2004, which highlighted the need for rigorous safety standards. As a result, companies like UniQure now face significant challenges in navigating these regulations to secure market approval and maintain investor trust.

1 of 2

Story summary

A senior official from the U.S. Food and Drug Administration (FDA) called UniQure's Huntington's disease gene therapy a "failed product" during a media call.
The FDA has requested a new placebo-controlled study, disputing UniQure's ethics claim.
The official said UniQure's previous trial design did not demonstrate the therapy's effectiveness.
UniQure's stock rose 19% to $10.75 after the announcement, reflecting the FDA's long-standing policy requiring rigorous trial designs for Huntington's treatments.

1 / 2